About the bill
There are 30 million Americans living with what S. 139 calls “rare diseases or conditions.” It is difficult enough facing such disorders, but it can be even more difficult finding those willing to participate in clinical trials to provide information, treat and perhaps even cure these conditions. The definition of “rare disease” in the U.S. is “any disease or condition where the prevalence is less than 200,000 patients.” In an interview in pharmaphorum Yaffa Rubenstein, of the Office of Rare Diseases Research (ORDR), explained there are “...more than 6,800 rare diseases known today.”
On September 28, 2015, Congress maintained federal support for the participation of low-income Americans in clinical trials for these conditions. The bill, titled “Ensuring Access to Clinical Trials,” includes renewal of the Improving Access to Clinical …
Sponsor and status
Sponsor. Senator for Oregon. Democrat.
Last Updated: Oct 6, 2016
Length: 1 page
What legislators are saying
Jan 8, 2015
Bills and resolutions are referred to committees which debate the bill before possibly sending it on to the whole chamber.
Jul 16, 2015
Passed Senate (House next)
The bill was passed in a vote in the Senate. It goes to the House next. The vote was by Unanimous Consent so no record of individual votes was made.
Sep 28, 2015
The bill was passed by both chambers in identical form. It goes to the President next who may sign or veto the bill. The vote was by voice vote so no record of individual votes was made.
Oct 7, 2015
Enacted — Signed by the President
The President signed the bill and it became law.
S. 139 (114th) was a bill in the United States Congress.
A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.
Bills numbers restart every two years. That means there are other bills with the number S. 139. This is the one from the 114th Congress.
This bill was introduced in the 114th Congress, which met from Jan 6, 2015 to Jan 3, 2017. Legislation not passed by the end of a Congress is cleared from the books.
How to cite this information.
We recommend the following MLA-formatted citation when using the information you see here in academic work:
GovTrack.us. (2022). S. 139 — 114th Congress: Ensuring Access to Clinical Trials Act of 2015. Retrieved from https://www.govtrack.us/congress/bills/114/s139
“S. 139 — 114th Congress: Ensuring Access to Clinical Trials Act of 2015.” www.GovTrack.us. 2015. May 24, 2022 <https://www.govtrack.us/congress/bills/114/s139>
Ensuring Access to Clinical Trials Act of 2015, Pub. L. No. 114-63, S. 139, 114th Cong..
|title=S. 139 (114th)
|accessdate=May 24, 2022
|author=114th Congress (2015)
|date=January 8, 2015
|quote=Ensuring Access to Clinical Trials Act of 2015
Where is this information from?
GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.